480 research outputs found

    Analytical study of waterlogged ivory from the Bajo de la campana site (Murcia, Spain)

    Full text link
    [EN] This work reports an analytical study conducted prior to the conservation intervention of a collection of elephant tusks excavated from a wreck site of a 600-500 BC Phoenician trading vessel in Bajo de la campana (Murcia, Spain). The conservation state of ivory, determined by prolongated immersion in a marine environment, was established by a multi-technique methodology: light microscopy, field emission scanning electron microscopy X-ray microanalysis (FESEM-EDX), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), spectrophotometry and gas chromatography-mass spectrometry (GC-MS). The analyses demonstrated that the structure and composition of both tusk parts, namely the inner ivory and outer cementum, were altered due to characteristic diagenetic processes of a marine environment. Ca enrichment was observed in both tusk parts, which gave higher Ca/P molar ratio values than for ideal hydroxyapatite. Mg leaching was observed, together with uptake of exogenous elements (F, Cl, Si, Al, S, Na, Fe, Cu, Sr, Pb, Sn, Ag, V, Ni, Cd and Zn), which were prevalently identified in the external tusk part. Uptake of S and Fe was associated with the neoformation of pyrite framboids. The high carbonate content measured by FTIR, which agreed with the higher Ca/P ratios found in the archaeological tusk, was ascribed to the carbonate substitution of phosphate groups (type-B) in the bioapatite accompanied by some authigenic calcium carbonate that infilled ivory. An increased degree of crystallinity was observed when comparing the values of several crystallinity indices found in the archaeological bioapatite with those of a modern tusk, used as the reference material. Increased crystallinity prevalently took place in the cementurn. In accordance with increased crystallinity, the HPO42- content index indicated that the hydrated layer of bioapatite nanocrystals diminished in the archaeological tusk, and prevalently in the cementum. All these changes correlated with the significant organic matter loss reported for the archaeological tusk. Interestingly, remaining collagenous matter noticeably altered with enrichment in glycine and depletion in acid amino acids. Changes in the secondary structure of proteins were also recognised and associated with collagen gelatinisation. In addition to proteinaceous materials, small amounts of long-chain fatty acids, monoglycerides and cholesteryl oleate were identified by GC-MS. Cholesteryl oleate was associated with blood, which could have precipitated at the time of specimen death. The identification of large amounts of pyrite framboids and the high oleic acid/palmitic acid ratio in the archaeological tusk suggested minimal oxidative degradation processes, probably due to the slightly anoxic conditions of the underwater Bajo de la campana site environment. (C) 2016 Elsevier B.V. All rights reserved.The authors wish to thank CITES Espana and Direccion General de Bienes Culturales y Ensenanzas Artisticas, de la Consejeria de Educacion, Cultura y Universidades de la Comunidad Autonoma de la Region de Murcia, Museo Nacional de Arqueologia Subacuatica. Financial support is gratefully acknowledged from Spanish "I + D + I MINECO" projects CTQ2011-28079-CO3-01 and 02 and CTQ2014-53736-C3-1-P supported by ERDEF funds. The authors also wish to thank Mr. Manuel Planes and Dr. Jose Luis Moya, technical supervisors of the Electron Microscopy Service of the Universitat Politecnica de Valencia.Domenech Carbo, MT.; Buendía Ortuño, MDM.; Pasies Oviedo, T.; Osete Cortina, L. (2016). Analytical study of waterlogged ivory from the Bajo de la campana site (Murcia, Spain). Microchemical Journal. 126:381-405. https://doi.org/10.1016/j.microc.2015.12.022S38140512

    Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study

    Get PDF
    Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≄ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe

    Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

    Get PDF
    Background Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide.Methods A multimethods analysis was performed as part of the GlobalSurg 3 study-a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital.Findings Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3.85 [95% CI 2.58-5.75]; p&lt;0.0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63.0% vs 82.7%; OR 0.35 [0.23-0.53]; p&lt;0.0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer.Interpretation Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised

    A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

    Get PDF
    Purpose Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the “ClinVar low-hanging fruit” reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion The “ClinVar low-hanging fruit” analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock

    Study of genetic causes of vitamin D metabolism dysregulation

    No full text
    La vitamine D (D3 ou cholĂ©calcifĂ©rol du rĂšgne animal et D2 ou ergostĂ©rol du rĂšgne vĂ©gĂ©tal) est une hormone plĂ©iotrope qui possĂšde de nombreux effets biologiques incluant la rĂ©gulation du mĂ©tabolisme du calcium et du phosphate. Chez l’Homme, ce composĂ© est synthĂ©tisĂ© au niveau cutanĂ© sous forme inactive. On dĂ©crit ainsi le mĂ©tabolisme de la vitamine D qui conduit Ă  la production de mĂ©tabolites actifs (par les vitamine D 25- et 1α-hydroxylases codĂ©es par les gĂšnes CYP2R1 et CYP27B1) et Ă  leur dĂ©gradation par la vitamine D 24-hydroxylase (gĂšne CYP24A1). L’expression des vitamine 1α- et 24-hydroxylases est finement et inversement rĂ©gulĂ©e afin de maintenir l’homĂ©ostasie phosphocalcique, grĂące Ă  plusieurs boucles de rĂ©trocontrĂŽle impliquant entre autres la forme 1,25-dihydroxylĂ©e de la vitamine D et son rĂ©cepteur VDR, la calcĂ©mie et la parathormone, la phosphatĂ©mie et le FGF23. La carence en vitamine D et les dĂ©fauts de son activation sont associĂ©s Ă  un phĂ©notype de rachitisme, tandis que les excĂšs en vitamine D sont associĂ©s Ă  un phĂ©notype d’hypercalcĂ©mie-hypercalciurie par intoxication (surdosage) ou hypersensibilitĂ© Ă  la vitamine D (excĂšs d’activation ou dĂ©faut de dĂ©gradation).L’objectif de ce travail de thĂšse est d’identifier des causes gĂ©nĂ©tiques de dĂ©rĂ©gulation du mĂ©tabolisme de la vitamine D et de prĂ©ciser leurs mĂ©canismes physiopathologiques par une description prĂ©cise du phĂ©notype associĂ©. Pour ce faire, nous avons utilisĂ© de façon conjointe les outils de la gĂ©nĂ©tique (sĂ©quençage nouvelle gĂ©nĂ©ration et Sanger) et de la biochimie (dosage des mĂ©tabolites) dans une cohorte de patients recrutĂ©s grĂące au centre de rĂ©fĂ©rence maladies rares du mĂ©tabolisme du calcium et du phosphate.Ce travail a permis de prĂ©ciser le rĂŽle de deux gĂšnes dans les maladies liĂ©es Ă  la dĂ©rĂ©gulation mĂ©tabolisme de la vitamine D, CYP2R1 et CYP24A1, par la mise en Ă©vidence de mutations perte de fonction chez des patients avec un phĂ©notype de rachitisme Ă  25-hydroxyvitamine D basse et d’hypersensibilitĂ© Ă  la vitamine D respectivement. Notre Ă©tude a permis aussi de prĂ©ciser le phĂ©notype de ces affections. Dans la cohorte des patients Ă©tudiĂ©s, l’identification de mutations de gĂšnes impactant le mĂ©tabolisme du phosphate (SLC34A1 et SLC34A3), souligne l’intĂ©rĂȘt de l’étude des facteurs rĂ©gulateurs des activitĂ©s vitamine D 1α- et 24-hydroxylases.Aucune variation significative dans les rĂ©gions promotrices proximales de CYP27B1 et CYP24A1 n’a Ă©tĂ© identifiĂ©e. Le peu de connaissances sur l’ensemble des Ă©lĂ©ments rĂ©gulateurs chez l’Homme n’a pas permis d’approfondir notre Ă©tude. L’identification et l’étude de ces Ă©lĂ©ments rĂ©gulateurs distaux permettra de dĂ©terminer leur implication dans les maladies rares du mĂ©tabolisme de la vitamine D.The vitamin D (D3 or cholecalciferol from animal kingdom and D2 or ergosterol from plan kingdom) is a pleiotropic hormone who has numerous biological effects including the regulation of calcium and phosphate metabolism. In humans, this compound is synthetized in skin in an inactive form. Thus, we call vitamin D metabolism the biological process which leads to the production of active metabolites (by enzymes 25- and 1α-hydroxylases encoded by CYP2R1 and CYP27B1 genes) and its degradation by vitamin D 24-hydroxylase (gene CYP24A1). The expression of 1α- and 24-hydroxylases is tightly and inversely regulated to maintain calcium and phosphate homeostasis, thanks to several feedback loops including 1,25-dihydroxyvitamin D and its receptor VDR, serum calcium and parathormone, serum phosphate and FGF23. Vitamin D deficiency and vitamin D activation deficiency are associated with rickets, while vitamin D excess are associated with hypercalcemia-hypercalciuria due to vitamin D intoxication (overdose) or hypersensitivity to vitamin D (activation excess or degradation deficiency).Our aim is to identify genetic causes of vitamin D metabolism deregulation and to specify pathophysiologic mechanisms describing phenotype. Thus, we jointly used the tools of genetics (next-generation and Sanger sequencing) and biochemistry (vitamin D metabolites assay) in a cohort of human patients ascertained thanks to the national center for rare diseases of calcium and phosphate metabolism.This work allowed us to specify the role of two genes in diseases of vitamin D metabolism, CYP2R1 and CYP24A1, showing loss of function mutations in patients with rickets and low 25-hydroxyvitamin D and hypersensitivity to vitamin D, respectively. Our study brought new phenotypic elements in these affections. In our cohort of patients, the identification of mutations leading to phosphate deregulation (in SLC34A1 and SLC34A3) highlights the putative role of regulators of vitamin D 1α- and 24-hydroxylases activities in pathophysiology.No significant variation have been identified in the proximal promoting regions of CYP27B1 and CYP24A1. We could not go further considering the lack of knowledge in regulating regions and factors in humans. Identifying distal regulators will allow to study their implication in rare diseases of vitamin D metabolism

    Etude des causes génétiques de dérégulation du métabolisme de la vitamine D

    Get PDF
    The vitamin D (D3 or cholecalciferol from animal kingdom and D2 or ergosterol from plan kingdom) is a pleiotropic hormone who has numerous biological effects including the regulation of calcium and phosphate metabolism. In humans, this compound is synthetized in skin in an inactive form. Thus, we call vitamin D metabolism the biological process which leads to the production of active metabolites (by enzymes 25- and 1α-hydroxylases encoded by CYP2R1 and CYP27B1 genes) and its degradation by vitamin D 24-hydroxylase (gene CYP24A1). The expression of 1α- and 24-hydroxylases is tightly and inversely regulated to maintain calcium and phosphate homeostasis, thanks to several feedback loops including 1,25-dihydroxyvitamin D and its receptor VDR, serum calcium and parathormone, serum phosphate and FGF23. Vitamin D deficiency and vitamin D activation deficiency are associated with rickets, while vitamin D excess are associated with hypercalcemia-hypercalciuria due to vitamin D intoxication (overdose) or hypersensitivity to vitamin D (activation excess or degradation deficiency).Our aim is to identify genetic causes of vitamin D metabolism deregulation and to specify pathophysiologic mechanisms describing phenotype. Thus, we jointly used the tools of genetics (next-generation and Sanger sequencing) and biochemistry (vitamin D metabolites assay) in a cohort of human patients ascertained thanks to the national center for rare diseases of calcium and phosphate metabolism.This work allowed us to specify the role of two genes in diseases of vitamin D metabolism, CYP2R1 and CYP24A1, showing loss of function mutations in patients with rickets and low 25-hydroxyvitamin D and hypersensitivity to vitamin D, respectively. Our study brought new phenotypic elements in these affections. In our cohort of patients, the identification of mutations leading to phosphate deregulation (in SLC34A1 and SLC34A3) highlights the putative role of regulators of vitamin D 1α- and 24-hydroxylases activities in pathophysiology.No significant variation have been identified in the proximal promoting regions of CYP27B1 and CYP24A1. We could not go further considering the lack of knowledge in regulating regions and factors in humans. Identifying distal regulators will allow to study their implication in rare diseases of vitamin D metabolism.La vitamine D (D3 ou cholĂ©calcifĂ©rol du rĂšgne animal et D2 ou ergostĂ©rol du rĂšgne vĂ©gĂ©tal) est une hormone plĂ©iotrope qui possĂšde de nombreux effets biologiques incluant la rĂ©gulation du mĂ©tabolisme du calcium et du phosphate. Chez l’Homme, ce composĂ© est synthĂ©tisĂ© au niveau cutanĂ© sous forme inactive. On dĂ©crit ainsi le mĂ©tabolisme de la vitamine D qui conduit Ă  la production de mĂ©tabolites actifs (par les vitamine D 25- et 1α-hydroxylases codĂ©es par les gĂšnes CYP2R1 et CYP27B1) et Ă  leur dĂ©gradation par la vitamine D 24-hydroxylase (gĂšne CYP24A1). L’expression des vitamine 1α- et 24-hydroxylases est finement et inversement rĂ©gulĂ©e afin de maintenir l’homĂ©ostasie phosphocalcique, grĂące Ă  plusieurs boucles de rĂ©trocontrĂŽle impliquant entre autres la forme 1,25-dihydroxylĂ©e de la vitamine D et son rĂ©cepteur VDR, la calcĂ©mie et la parathormone, la phosphatĂ©mie et le FGF23. La carence en vitamine D et les dĂ©fauts de son activation sont associĂ©s Ă  un phĂ©notype de rachitisme, tandis que les excĂšs en vitamine D sont associĂ©s Ă  un phĂ©notype d’hypercalcĂ©mie-hypercalciurie par intoxication (surdosage) ou hypersensibilitĂ© Ă  la vitamine D (excĂšs d’activation ou dĂ©faut de dĂ©gradation).L’objectif de ce travail de thĂšse est d’identifier des causes gĂ©nĂ©tiques de dĂ©rĂ©gulation du mĂ©tabolisme de la vitamine D et de prĂ©ciser leurs mĂ©canismes physiopathologiques par une description prĂ©cise du phĂ©notype associĂ©. Pour ce faire, nous avons utilisĂ© de façon conjointe les outils de la gĂ©nĂ©tique (sĂ©quençage nouvelle gĂ©nĂ©ration et Sanger) et de la biochimie (dosage des mĂ©tabolites) dans une cohorte de patients recrutĂ©s grĂące au centre de rĂ©fĂ©rence maladies rares du mĂ©tabolisme du calcium et du phosphate.Ce travail a permis de prĂ©ciser le rĂŽle de deux gĂšnes dans les maladies liĂ©es Ă  la dĂ©rĂ©gulation mĂ©tabolisme de la vitamine D, CYP2R1 et CYP24A1, par la mise en Ă©vidence de mutations perte de fonction chez des patients avec un phĂ©notype de rachitisme Ă  25-hydroxyvitamine D basse et d’hypersensibilitĂ© Ă  la vitamine D respectivement. Notre Ă©tude a permis aussi de prĂ©ciser le phĂ©notype de ces affections. Dans la cohorte des patients Ă©tudiĂ©s, l’identification de mutations de gĂšnes impactant le mĂ©tabolisme du phosphate (SLC34A1 et SLC34A3), souligne l’intĂ©rĂȘt de l’étude des facteurs rĂ©gulateurs des activitĂ©s vitamine D 1α- et 24-hydroxylases.Aucune variation significative dans les rĂ©gions promotrices proximales de CYP27B1 et CYP24A1 n’a Ă©tĂ© identifiĂ©e. Le peu de connaissances sur l’ensemble des Ă©lĂ©ments rĂ©gulateurs chez l’Homme n’a pas permis d’approfondir notre Ă©tude. L’identification et l’étude de ces Ă©lĂ©ments rĂ©gulateurs distaux permettra de dĂ©terminer leur implication dans les maladies rares du mĂ©tabolisme de la vitamine D

    Le rachitisme (un fléau endémique devenu maladie rare ?)

    No full text
    CAEN-BU MĂ©decine pharmacie (141182102) / SudocSudocFranceF

    CO-28 HypersensibilitĂ© Ă  la vitamine D : Ă©tude molĂ©culaire d’une cohorte de 185 patients.

    No full text
    National audienceIntroduction : Des mutations des gĂšnes CYP24A1 codant la vitamine D 24-hydroxylase, et plus rĂ©cemment SLC34A1 et SLC34A3 codant les cotransporteurs rĂ©naux sodium-phosphate, ont Ă©tĂ© associĂ©es au phĂ©notype d’hypersensibilitĂ© Ă  la vitamine D (HVD). Ce phĂ©notype comprend une calcĂ©mie Ă©levĂ©e et une PTH basse, des hypercalcĂ©mies aigues en cas de prise de vitamine D, des complications de l’hypercalciurie chronique (lithiase rĂ©nale, nĂ©phrocalcinose).Objectifs : Evaluer la contribution de ces gĂšnes au phĂ©notype HVD et identifier un profil biologique spĂ©cifique susceptible de guider l’analyse molĂ©culaire.Patients/MĂ©thodes : Etude par NGS des gĂšnes CYP24A1, SLC34A1, SLC34A3 et SLC9A3R1 (lithiase rĂ©nale avec hypophosphatĂ©mie) dans une cohorte de 185 patients prĂ©sentant une hypercalcĂ©mie et/ou une hypercalciurie avec PTH <20 pg/mL.RĂ©sultats : Nous avons identifiĂ© 34 (18%) patients avec mutations CYP24A1 (26 (14%) biallĂ©liques et 8 (4%) hĂ©tĂ©rozygotes), 18 (10%) patients avec mutations SLC34A1 (5 (3%) biallĂ©liques et 13 (7%) hĂ©tĂ©rozygotes), 13 (7%) patients avec mutations SLC34A3 (6 (3%) biallĂ©liques et 7 (4%) hĂ©tĂ©rozygotes), aucun patient avec mutation SLC9A3R1. Deux (1%) patients prĂ©sentent une double hĂ©tĂ©rozygotie (SLC34A1/SLC34A3 et CYP24A1/SLC34A3). Parmi les patients avec mutation biallĂ©lique, les patients SLC34A3 prĂ©sentent une calcĂ©mie et une phosphatĂ©mie plus basses. Les sujets hĂ©tĂ©rozygotes pour ces 3 gĂšnes prĂ©sentent des valeurs de 1,25-(OH)2D plus Ă©levĂ©es que les patients avec mutation biallĂ©lique.Schlingmann et al. N Engl J Med. 2011 Aug 4;365(5):410-21.Schlingmann et al. J Am Soc Nephrol. 2016 Feb;27(2):604-14.Dasgupta et al. J Am Soc Nephrol. 2014 Oct;25(10):2366-75
    • 

    corecore